CR IMO is better at this point in the business, less risk involved of not servicing the loan, if sales does not materialise within a reasonable timeframe. Also the register this is not huge so I don't see dilution as being an issue.
Djwally's original post around CR IMO summarised what is likely happening really well. If he is correct, then I think this shop is being run very well and we are unlikely to see a CR for a little while. When we do, it is either for a large order and/or significant ramp up of distribution costs after obtaining FDA. By that stage, if they don't do a CR, I'd be screaming at them to do one lol.
GLTAH
Ann: US Clinical Trial Results Published, page-68
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
